Glaukos (NYSE: GKOS) lifts 2026 sales outlook after 50% Q2 revenue jump
Rhea-AI Filing Summary
Glaukos Corporation reported record second-quarter 2026 net sales of $185.6 million, up 50% year over year on a reported basis, driven primarily by growing adoption of iDose TR and early Epioxa contributions. Glaucoma revenue reached $155.2 million, including U.S. glaucoma of $118.5 million, while Corneal Health delivered $30.4 million, including about $11 million from Epioxa. GAAP gross margin was approximately 82% and non-GAAP gross margin about 85%. The company remained loss-making, with GAAP net loss of $18.4 million and non-GAAP net loss of $8.3 million, both narrower than the prior year.
Selling, general and administrative expenses rose to $116.1 million (non-GAAP $111.7 million) and R&D to $51.3 million as Glaukos invested in commercialization and its pipeline, including a $1.5 million acquired in-process R&D charge. The company ended the quarter with about $289.3 million in cash, short-term investments and restricted cash and no debt. Reflecting strong momentum, Glaukos raised its 2026 net sales outlook to $680–$700 million, up from $620–$635 million, supported by iDose TR, Epioxa and broader interventional glaucoma initiatives.
Positive
- Record Q2 2026 net sales of $185.6 million, up 50% year over year, driven by glaucoma and corneal franchises, including contributions from iDose TR and Epioxa.
- 2026 net sales guidance raised to $680–$700 million from $620–$635 million, indicating management’s expectation of continued strong demand momentum.
- Non-GAAP net loss narrowed to $8.3 million and non-GAAP loss per share to $0.14 from $0.24 a year earlier, reflecting improved operating leverage.
Negative
- Company remains unprofitable, reporting a GAAP net loss of $18.4 million in Q2 2026 amid significantly higher SG&A and R&D spending.
Filing Explained
Common shares outstanding rose to 58,858 thousand by June 30, while 2026 sales guidance remains an expectation pending the next quarterly filing.
The company’s Form 8-K reports completed second-quarter results for the period ended
Form 8-K is a current-report form for specified material events; here, Items 2.02 and 7.01 furnish the results and supplemental quarterly information rather than documenting a financing or completed securities sale.
The
The next stated reporting milestone is the company’s Form 10-Q for the quarter ended
8-K Event Classification
Key Figures
Key Terms
Micro-Invasive Glaucoma Surgery (MIGS) medical
intracameral procedural pharmaceutical medical
epithelium-on corneal cross-linking medical
non-GAAP gross margin financial
constant currency financial
Offering Details
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Glaukos (GKOS) Q2 2026 revenues and year-over-year growth?
How did 2026 sales guidance change for Glaukos (GKOS)?
Did Glaukos (GKOS) achieve profitability in Q2 2026?
How did iDose TR and Epioxa contribute to Glaukos (GKOS) Q2 2026 results?
What was Glaukos (GKOS) cash and debt position at June 30, 2026?
What were Glaukos (GKOS) gross margin and expense trends in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 29, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure.
A Quarterly Summary containing supplemental business and financial information for the Company’s second quarter ended June 30, 2026 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com.
The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release of Glaukos Corporation, dated July 29, 2026 |
99.2 |
|
Quarterly Summary of Glaukos Corporation for the second quarter ended June 30, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GLAUKOS CORPORATION (Registrant) |
||
|
|
||
|
By: |
/s/ Alex R. Thurman |
|
|
|
Name: |
Alex R. Thurman |
|
|
Title: |
Senior Vice President & Chief Financial Officer |
Date: July 29, 2026
|
Exhibit 99.1 |
FOR IMMEDIATE RELEASE
Contact:
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
clewis@glaukos.com
Glaukos Announces Second Quarter 2026 Financial Results
Aliso Viejo, CA – July 29, 2026 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include:
“Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Second Quarter 2026 Financial Results
Net sales in the second quarter of 2026 of $185.6 million increased 50% on a reported basis, or 49% on a constant currency basis, compared to $124.1 million in the same period in 2025.
Gross margin for the second quarter of 2026 was approximately 82%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the second quarter of 2026 was approximately 85%, compared to approximately 83% in the same period in 2025.
Selling, general and administrative (SG&A) expenses for the second quarter of 2026 increased 39% to $116.1 million, compared to $83.4 million in the same period in 2025. Non-GAAP SG&A expenses for the second quarter of 2026 increased 34% to $111.7 million, compared to $83.1 million in the same period in 2025.
GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2026 increased 40% to $51.3 million, compared to $36.5 million in the same period in 2025.
Loss from operations in the second quarter of 2026 was $17.3 million, compared to operating loss of $22.7 million in the second quarter of 2025. Non-GAAP loss from operations in the second quarter of 2026 was $7.6 million, compared to non-GAAP operating loss of $16.6 million in the second quarter of 2025.
Net loss in the second quarter of 2026 was $18.4 million, or ($0.31) per diluted share, compared to net loss of $19.7 million, or ($0.34) per diluted share, in the second quarter of 2025. Non-GAAP net loss in the second
1
quarter of 2026 was $8.3 million, or ($0.14) per diluted share, compared to non-GAAP net loss of $13.6 million, or ($0.24) per diluted share, in the second quarter of 2025.
Included in non-GAAP loss from operations, non-GAAP net loss, and non-GAAP EPS for the second quarter of 2026 is an acquired in-process R&D (IPR&D) charge of $1.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.02) in the second quarter of 2026.
The company ended the second quarter of 2026 with approximately $289.3 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.
2026 Revenue Guidance
The company expects 2026 net sales to be in the range of $680 million to $700 million based on the latest foreign currency exchange rates.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 626961391. A replay of the webcast will be archived on the company’s website following completion of the call.
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events
2
or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; risks related to our capped call transactions; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on April 30, 2026, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which we expect to file on or before August 10, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs
3
incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
4
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Net sales |
|
$ |
185,610 |
|
|
$ |
124,120 |
|
|
$ |
336,181 |
|
|
$ |
230,784 |
|
Cost of sales |
|
|
34,016 |
|
|
|
26,896 |
|
|
|
67,355 |
|
|
|
51,212 |
|
Gross profit |
|
|
151,594 |
|
|
|
97,224 |
|
|
|
268,826 |
|
|
|
179,572 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
116,060 |
|
|
|
83,375 |
|
|
|
209,003 |
|
|
|
154,048 |
|
Research and development |
|
|
51,301 |
|
|
|
36,538 |
|
|
|
95,446 |
|
|
|
68,891 |
|
Acquired in-process research and development |
|
|
1,500 |
|
|
|
- |
|
|
|
1,500 |
|
|
|
- |
|
Total operating expenses |
|
|
168,861 |
|
|
|
119,913 |
|
|
|
305,949 |
|
|
|
222,939 |
|
Loss from operations |
|
|
(17,267 |
) |
|
|
(22,689 |
) |
|
|
(37,123 |
) |
|
|
(43,367 |
) |
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
2,279 |
|
|
|
2,574 |
|
|
|
4,710 |
|
|
|
5,650 |
|
Interest expense |
|
|
(1,459 |
) |
|
|
(1,151 |
) |
|
|
(2,584 |
) |
|
|
(2,314 |
) |
Other (expense) income, net |
|
|
(1,274 |
) |
|
|
1,857 |
|
|
|
(2,023 |
) |
|
|
2,802 |
|
Total non-operating (expense) income |
|
|
(454 |
) |
|
|
3,280 |
|
|
|
103 |
|
|
|
6,138 |
|
Loss before taxes |
|
|
(17,721 |
) |
|
|
(19,409 |
) |
|
|
(37,020 |
) |
|
|
(37,229 |
) |
Income tax provision |
|
|
656 |
|
|
|
248 |
|
|
|
1,140 |
|
|
|
574 |
|
Net loss |
|
$ |
(18,377 |
) |
|
$ |
(19,657 |
) |
|
$ |
(38,160 |
) |
|
$ |
(37,803 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted net loss per share |
|
$ |
(0.31 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.65 |
) |
|
$ |
(0.66 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average shares outstanding used to |
|
|
58,818 |
|
|
|
57,205 |
|
|
|
58,419 |
|
|
|
56,922 |
|
5
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
114,485 |
|
|
$ |
90,813 |
|
Short-term investments |
|
|
171,741 |
|
|
|
187,947 |
|
Accounts receivable, net |
|
|
138,900 |
|
|
|
108,608 |
|
Inventory |
|
|
59,306 |
|
|
|
63,564 |
|
Prepaid expenses and other current assets |
|
|
31,346 |
|
|
|
24,052 |
|
Total current assets |
|
|
515,778 |
|
|
|
474,984 |
|
Restricted cash |
|
|
3,115 |
|
|
|
3,834 |
|
Property and equipment, net |
|
|
112,114 |
|
|
|
113,253 |
|
Operating lease right-of-use asset |
|
|
31,271 |
|
|
|
31,527 |
|
Finance lease right-of-use asset |
|
|
38,197 |
|
|
|
39,404 |
|
Intangible assets, net |
|
|
127,151 |
|
|
|
141,916 |
|
Goodwill |
|
|
66,710 |
|
|
|
66,710 |
|
Deposits and other assets |
|
|
26,185 |
|
|
|
21,859 |
|
Total assets |
|
$ |
920,521 |
|
|
$ |
893,487 |
|
|
|
|
|
|
|
|
||
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
19,139 |
|
|
$ |
24,624 |
|
Accrued liabilities |
|
|
83,190 |
|
|
|
76,651 |
|
Total current liabilities |
|
|
102,329 |
|
|
|
101,275 |
|
Operating lease liability |
|
|
35,491 |
|
|
|
35,767 |
|
Finance lease liability |
|
|
67,345 |
|
|
|
68,109 |
|
Deferred tax liability, net |
|
|
441 |
|
|
|
441 |
|
Other liabilities |
|
|
32,429 |
|
|
|
31,740 |
|
Total liabilities |
|
|
238,035 |
|
|
|
237,332 |
|
|
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value; 5,000 shares authorized; no |
|
|
- |
|
|
|
- |
|
Common stock, $0.001 par value; 150,000 shares authorized; 58,886 |
|
|
59 |
|
|
|
58 |
|
Additional paid-in capital |
|
|
1,651,465 |
|
|
|
1,586,056 |
|
Accumulated other comprehensive income |
|
|
2,384 |
|
|
|
3,303 |
|
Accumulated deficit |
|
|
(971,290 |
) |
|
|
(933,130 |
) |
Less treasury stock (28 shares as of June 30, 2026 and December 31, |
|
|
(132 |
) |
|
|
(132 |
) |
Total stockholders' equity |
|
|
682,486 |
|
|
|
656,155 |
|
Total liabilities and stockholders' equity |
|
$ |
920,521 |
|
|
$ |
893,487 |
|
6
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
|
|
Q2 2026 |
|
|
Q2 2025 |
|
||||||||||||||||||
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
||||||
Cost of sales |
|
$ |
34,016 |
|
|
$ |
(5,274 |
) |
(a)(b) |
$ |
28,742 |
|
|
$ |
26,896 |
|
|
$ |
(5,764 |
) |
(a)(b) |
$ |
21,132 |
|
Gross Margin |
|
|
81.7 |
% |
|
|
2.8 |
% |
|
|
84.5 |
% |
|
|
78.3 |
% |
|
|
4.7 |
% |
|
|
83.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Selling, general and administrative |
|
$ |
116,060 |
|
|
$ |
(4,404 |
) |
(c)(d)(e) |
$ |
111,656 |
|
|
$ |
83,375 |
|
|
$ |
(295 |
) |
(f) |
$ |
83,080 |
|
Loss from operations |
|
$ |
(17,267 |
) |
|
$ |
9,678 |
|
|
$ |
(7,589 |
) |
|
$ |
(22,689 |
) |
|
$ |
6,059 |
|
|
$ |
(16,630 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest expense |
|
$ |
(1,459 |
) |
|
$ |
369 |
|
(g) |
$ |
(1,090 |
) |
|
$ |
(1,151 |
) |
|
$ |
- |
|
|
$ |
(1,151 |
) |
Net loss |
|
$ |
(18,377 |
) |
|
$ |
10,047 |
|
(h) |
$ |
(8,330 |
) |
|
$ |
(19,657 |
) |
|
$ |
6,059 |
|
(h) |
$ |
(13,598 |
) |
Basic and diluted net loss per share |
|
$ |
(0.31 |
) |
|
$ |
0.17 |
|
|
$ |
(0.14 |
) |
|
$ |
(0.34 |
) |
|
$ |
0.10 |
|
|
$ |
(0.24 |
) |
7
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
|
|
Year-to-Date Q2 2026 |
|
|
Year-to-Date Q2 2025 |
|
||||||||||||||||||
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
||||||
Cost of sales |
|
$ |
67,355 |
|
|
$ |
(13,949 |
) |
(a)(b) |
$ |
53,406 |
|
|
$ |
51,212 |
|
|
$ |
(11,287 |
) |
(a)(b) |
$ |
39,925 |
|
Gross Margin |
|
|
80.0 |
% |
|
|
4.1 |
% |
|
|
84.1 |
% |
|
|
77.8 |
% |
|
|
4.9 |
% |
|
|
82.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Selling, general and administrative |
|
$ |
209,003 |
|
|
$ |
(5,097 |
) |
(c)(d)(e) |
$ |
203,906 |
|
|
$ |
154,048 |
|
|
$ |
(295 |
) |
(f) |
$ |
153,753 |
|
Loss from operations |
|
$ |
(37,123 |
) |
|
$ |
19,046 |
|
|
$ |
(18,077 |
) |
|
$ |
(43,367 |
) |
|
$ |
11,582 |
|
|
$ |
(31,785 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest expense |
|
$ |
(2,584 |
) |
|
$ |
369 |
|
(g) |
$ |
(2,215 |
) |
|
$ |
(2,314 |
) |
|
$ |
- |
|
|
$ |
(2,314 |
) |
Net loss |
|
$ |
(38,160 |
) |
|
$ |
19,415 |
|
(h) |
$ |
(18,745 |
) |
|
$ |
(37,803 |
) |
|
$ |
11,582 |
|
(h) |
$ |
(26,221 |
) |
Basic and diluted net loss per share |
|
$ |
(0.65 |
) |
|
$ |
0.33 |
|
|
$ |
(0.32 |
) |
|
$ |
(0.66 |
) |
|
$ |
0.20 |
|
|
$ |
(0.46 |
) |
8
Reported Sales vs. Prior Periods (in thousands) |
|
||||||||||||||||||||||||||
|
|
|
|
|
|
|
Year-over-Year Percent Change |
|
Quarter-over-Quarter Percent Change |
|
|||||||||||||||||
|
2Q 2026 |
|
2Q 2025 |
|
1Q 2026 |
|
Reported |
|
Operations (1) |
|
Currency (2) |
|
Reported |
|
Operations (1) |
|
Currency (2) |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
International Glaucoma |
$ |
36,631 |
|
$ |
31,251 |
|
$ |
35,808 |
|
|
17.2 |
% |
|
16.4 |
% |
|
0.8 |
% |
|
2.3 |
% |
|
2.6 |
% |
|
(0.3 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Total Net Sales |
$ |
185,610 |
|
$ |
124,120 |
|
$ |
150,571 |
|
|
49.5 |
% |
|
49.3 |
% |
|
0.2 |
% |
|
23.3 |
% |
|
23.3 |
% |
|
0.0 |
% |
9
Exhibit 99.2
|
JULY 29, 2026 |
GLAUKOS CORPORATION (NYSE: GKOS)
SECOND QUARTER 2026 IN REVIEW
Important Information
This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.
Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the “Additional Information” section of this document.
Conference Call Information
Date: |
|
July 29, 2026 |
|
|
|
Time: |
|
4:30 p.m. ET / 1:30 p.m. PT |
|
|
|
Dial-in numbers: |
|
1-833-461-5787 (U.S.), 1-585-542-9983 (International) |
|
|
|
Confirmation ID: |
|
626961391 |
|
|
|
Live webcast: |
|
Events page at the Glaukos Investor Relations website at http://investors.glaukos.com or at this link. |
|
|
|
Webcast replay: |
|
A replay of the webcast will be archived on the Glaukos Investor Relations website following completion of the call. |
1
|
JULY 29, 2026 |
SECOND QUARTER 2026 FINANCIAL RESULTS SUMMARY
Business Description |
Ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventional standard of care and improve outcomes for patients suffering from chronic eye diseases |
Disease Categories |
Glaucoma Corneal Health Retinal Disease |
Revenue (Growth) |
2Q 2026 $185.6 million (+50% reported and +49% constant currency versus 2Q 2025) |
Gross Margin (Non-GAAP) |
2Q 2026 ~85% (versus ~83% in 2Q 2025) |
Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash |
$289.3 million as of June 30, 2026 (versus $280.5 million as of March 31, 2026) |
FY2026 Sales Guidance |
FY 2026 global consolidated revenues of $680 - $700 million expected |
See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, and the other non-GAAP financial measures disclosed in this document to the most directly comparable GAAP financial measure are provided.
2
|
JULY 29, 2026 |
Revenue Performance & Commercial Overview
Global Consolidated Revenue Performance
Glaukos reported record second quarter net revenues of $185.6 million that were up 50% on a reported basis, or 49% on a constant currency basis, versus 2Q 2025. Our second quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as early contributions of Epioxa®.
Franchise Revenue Performance
3
|
JULY 29, 2026 |
U.S. Glaucoma
Our record second quarter U.S. Glaucoma net revenues were approximately $118.5 million, representing year-over-year growth of 64% versus 2Q 2025 driven by growing contributions from iDose TR, which generated sales of approximately $74 million in the second quarter.
During the second quarter, we successfully advanced execution of our commercialization of iDose TR, a first-of-its-kind intracameral procedural pharmaceutical that was designed to continuously deliver glaucoma drug therapy for up to three years. Most importantly, iDose TR continues to deliver strong clinical outcomes that meaningfully improve patients’ lives, resulting in strong physician interest and adoption while helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.
International Glaucoma
Our record second quarter International Glaucoma net revenues were approximately $36.6 million, representing year-over-year growth of 17% on a reported basis, or 16% on a constant currency basis, versus 2Q 2025. The strong growth internationally during the second quarter was broad-based as we continue to scale our international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market in the world.
We remain in the early stages of expanding our IG and product portfolio initiatives globally ahead of anticipated new product approvals and expanding market access in the years to come.
Corneal Health
Our record second quarter Corneal Health net revenues were approximately $30.4 million, representing year-over-year growth of 48% versus 2Q 2025, including Epioxa net sales of approximately $11 million.
During the second quarter, we advanced our initial commercial launch plans for Epioxa, our novel, groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. We believe Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to reduce the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.
As the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, Epioxa has been met with strong interest from surgeons and the broader ophthalmic community, reinforcing our confidence in its potential to redefine the treatment paradigm for this rare, sight-threatening disease.
We will continue to focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.
4
|
JULY 29, 2026 |
Additional Commercial Updates & Commentary
We have had several additional positive commercial updates worth highlighting here:
Advanced commercial launch activities in the U.S. for iDose TR
o Growing number of trained surgeons and accounts
o Increasing utilization by the installed active surgeon base
o Broadening and streamlining market access among MACs, commercial, and Medicare Advantage payers
o Expanded set of peer-reviewed literature, now consisting of 24 different peer-reviewed publications highlighting iDose TR as a transformative new treatment alternative for patients suffering with glaucoma and ocular hypertension
o Accelerating marketing investments to support increased patient awareness and education
Advanced initial commercial launch plans for Epioxa
o Epioxa commercial availability announced March 19, 2026
o Successfully established, and continue to selectively expand, a broad-reaching site-of-care network, with acquired O2N systems already actively deployed at locations covering roughly 85% of the U.S. population, and a broader pipeline of systems moving through approval processes that would expand our treatment reach to approximately 95%
o Market access:
Advancing efforts with payors to secure access pathways or policy coverage for Epioxa, with access pathways now established for more than 125 million covered commercial lives in the U.S., including with the 5 largest payors, reflecting encouraging initial receptivity of Epioxa’s clinical value
Product-specific J-code for Epioxa, J2789, became effective on July 1, 2026, and is expected to help streamline the reporting and reimbursement process for Epioxa among U.S. payors over time
o Deployed various new patient services and support programs
o Advancing targeted marketing and DTC campaigns designed to significantly enhance awareness, education, and detection, supported by greater optometric engagement and strengthened advocacy partnerships
o Expanded new financial co-pay assistance program and operationalized Specialty Pharmacy partner network in support of Epioxa patients
5
|
JULY 29, 2026 |
CMS’s Proposed Rules for Calendar Year 2027
o Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedules: Proposed to maintain the 2026 APC assignments and largely maintain facility fee rates associated with our procedures across both the hospital outpatient and ASC settings.
o Physician Fee Schedule (PFS) updates: Proposed modest reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including for cataract and surgical MIGS procedures specifically.
6
|
JULY 29, 2026 |
2026 Revenue Guidance Raised to Reflect Strong Momentum
Glaukos now expects full-year 2026 global consolidated net sales of $680 - $700 million, up from its previous guidance of $620 - $635 million. This guidance attempts to take into consideration:
Potential growing contributions from iDose TR as market access initiatives progress and broader IG initiatives take hold over the course of the year
Potential growing contributions from Epioxa as commercial launch plans advance and permanent J-code is effective and solidified operationally
Potential transient headwinds within our U.S. Corneal Health franchise during the third quarter associated with the Photrexa to Epioxa transition and ongoing operationalization of Epioxa’s now effective J-code
Potential growing contributions from iStent infinite as broader IG initiatives take hold
Uncertainties associated with five MAC’s proposed LCDs for iDose TR
Combo-cataract MIGS competition globally
The continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives
The latest foreign currency exchange spot rates as of our 2Q 2026 earnings call on July 29, 2026
Global macroeconomic and geopolitical environment and associated uncertainties, which at this time are difficult to predict
7
|
JULY 29, 2026 |
Research & Development / Pipeline Overview
Pipeline Summary
Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:
iStent® micro-scale surgical devices
iDose® sustained-release procedural pharmaceuticals
iLink® bio-activated pharmaceuticals
iLution™ transdermal pharmaceuticals
Retina XR bio-erodible sustained-release pharmaceuticals
8
|
JULY 29, 2026 |
Key R&D and Pipeline Updates
We are continuing to invest in and advance our fulsome pipeline of core novel platforms, supported by more than $900 million investment into R&D since 2018 alone. Recent updates in our pipeline include:
|
iDose Platform Updates |
Announced U.S. FDA approval for NDA labeling supplement allowing for unlimited re-administration of iDose TR in patients who maintain a healthy cornea (January 2026)
Advancing Phase 2b/3 clinical program for iDose TREX, our next-generation iDose therapy
o Initial results of Phase 2a clinical trial demonstrated substantial IOP reductions of 8.6 to 10.8 mmHg through 3 months
Completed patient enrollment in Phase 3b study for iDose TRIO
o Initial human factors study indicated strong user preference (~90% favorability)
Advancing various Phase 4 studies for iDose TR, including recently completed patient enrollment in Phase 4 study evaluating iDose TR + cataract surgery versus cataract surgery alone
|
iLink Platform Updates |
Announced U.S. FDA approval for Epioxa (Epi-on) (October 2025)
o Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated
o Epioxa ushers in a new standard of care for patients
Advancing development of KC screening device to support planned commercialization in 2H 2026
Preparing to commence Phase 3 clinical program for third-generation, customized, topography-guided iLink therapy in 2027
Advancing Phase 2 clinical trial for iVeena
9
|
JULY 29, 2026 |
|
iStent Platform Updates |
Completed patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients (4Q 2025)
Announced EU MDR certification for iStent infinite (June 2025)
Completed patient enrollment in 510(k) pivotal study for PRESERFLO™ MicroShunt (July 2026)
|
iLution Platform Updates |
Completed enrollment in Phase 2 clinical trial for iLution™ Blepharitis (2Q 2026)
|
Retina XR Platform Updates |
Completed patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401) (4Q 2025)
10
|
JULY 29, 2026 |
Product / Pipeline Chart
11
|
JULY 29, 2026 |
Other Financial Performance Overview
As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.
Second quarter 2026 financial performance summary:
|
2Q 2026: 85% 2Q 2025: 83% YoY ∆: +150 bps |
Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro and Mobius acquisitions accounting
|
|
2Q 2026: $111.7M 2Q 2025: $83.1M YoY ∆: +34% |
+21% sequential increase vs $92.2M in 1Q 2026 YoY and QoQ increases primarily reflect commercial and G&A investments globally and new product launch activities, along with approximately $15M in one-time stock compensation expenses associated with the triggering of certain performance awards in 2Q 2026 |
|
2Q 2026: $51.3M 2Q 2025: $36.5M YoY ∆: +40% |
+16% sequential increase vs $44.1M in 1Q 2026 YoY and QoQ increases primarily reflect continued investment in and advancement of R&D programs and clinical trials |
|
2Q 2026: $163.0M 2Q 2025: $119.6M YoY ∆: +36% |
+19% sequential increase vs $136.4M in 1Q 2026 |
|
Op Loss (Non-GAAP) 2Q 2026 ($7.6M) 2Q 2025: ($16.6M)
Net Loss (Non-GAAP) 2Q 2026: ($8.3M) 2Q 2025: ($13.6M)
Diluted EPS (Non-GAAP) 2Q 2026: ($0.14) 2Q 2025: ($0.24)
|
Included in non-GAAP loss from operations, non-GAAP net loss, and non-GAAP EPS for the second quarter of 2026 is an acquired in-process R&D (IPR&D) charge of $1.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.02) |
|
2Q 2026: $2.7M 2Q 2025: $1.2M YoY ∆: +$1.5M
|
Capital expenditures reflect normal course spend primarily on business maintenance activities and equipment upgrades
|
|
2Q 2026: $289.3M 1Q 2026: $280.5M QoQ ∆: +$8.8M
|
|
12
|
JULY 29, 2026 |
Other Important Updates
Given the ongoing conversations around tariff and broader geopolitical volatility, we wanted to reiterate that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related policies. That said, the global tariff environment remains fluid, and more broadly, the current geopolitical backdrop and macroeconomic uncertainties continue to evolve. As such, we will continue to closely monitor these situations given the overall instability in the marketplace and global macroeconomic uncertainties.
13
|
JULY 29, 2026 |
|
Additional Information |
14
|
JULY 29, 2026 |
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; risks related to our capped call transactions; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on April 30, 2026, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which we expect to file on or before August 10, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.
15
|
JULY 29, 2026 |
We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. Beginning in the second quarter of 2022, we no longer exclude certain upfront and contingent milestone payments in connection with collaborative and licensing arrangements and certain in-process R&D charges for non-GAAP reporting and disclosure purposes.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Additional GAAP to Non-GAAP Reconciliations” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
16
|
JULY 29, 2026 |
GAAP Income Statement
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Net sales |
|
$ |
185,610 |
|
|
$ |
124,120 |
|
|
$ |
336,181 |
|
|
$ |
230,784 |
|
Cost of sales |
|
|
34,016 |
|
|
|
26,896 |
|
|
|
67,355 |
|
|
|
51,212 |
|
Gross profit |
|
|
151,594 |
|
|
|
97,224 |
|
|
|
268,826 |
|
|
|
179,572 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
116,060 |
|
|
|
83,375 |
|
|
|
209,003 |
|
|
|
154,048 |
|
Research and development |
|
|
51,301 |
|
|
|
36,538 |
|
|
|
95,446 |
|
|
|
68,891 |
|
Acquired in-process research and development |
|
|
1,500 |
|
|
|
- |
|
|
|
1,500 |
|
|
|
- |
|
Total operating expenses |
|
|
168,861 |
|
|
|
119,913 |
|
|
|
305,949 |
|
|
|
222,939 |
|
Loss from operations |
|
|
(17,267 |
) |
|
|
(22,689 |
) |
|
|
(37,123 |
) |
|
|
(43,367 |
) |
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
2,279 |
|
|
|
2,574 |
|
|
|
4,710 |
|
|
|
5,650 |
|
Interest expense |
|
|
(1,459 |
) |
|
|
(1,151 |
) |
|
|
(2,584 |
) |
|
|
(2,314 |
) |
Other (expense) income, net |
|
|
(1,274 |
) |
|
|
1,857 |
|
|
|
(2,023 |
) |
|
|
2,802 |
|
Total non-operating (expense) income |
|
|
(454 |
) |
|
|
3,280 |
|
|
|
103 |
|
|
|
6,138 |
|
Loss before taxes |
|
|
(17,721 |
) |
|
|
(19,409 |
) |
|
|
(37,020 |
) |
|
|
(37,229 |
) |
Income tax provision |
|
|
656 |
|
|
|
248 |
|
|
|
1,140 |
|
|
|
574 |
|
Net loss |
|
$ |
(18,377 |
) |
|
$ |
(19,657 |
) |
|
$ |
(38,160 |
) |
|
$ |
(37,803 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic and diluted net loss per share |
|
$ |
(0.31 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.65 |
) |
|
$ |
(0.66 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average shares outstanding used to |
|
|
58,818 |
|
|
|
57,205 |
|
|
|
58,419 |
|
|
|
56,922 |
|
17
|
JULY 29, 2026 |
GAAP Balance Sheet
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
114,485 |
|
|
$ |
90,813 |
|
Short-term investments |
|
|
171,741 |
|
|
|
187,947 |
|
Accounts receivable, net |
|
|
138,900 |
|
|
|
108,608 |
|
Inventory |
|
|
59,306 |
|
|
|
63,564 |
|
Prepaid expenses and other current assets |
|
|
31,346 |
|
|
|
24,052 |
|
Total current assets |
|
|
515,778 |
|
|
|
474,984 |
|
Restricted cash |
|
|
3,115 |
|
|
|
3,834 |
|
Property and equipment, net |
|
|
112,114 |
|
|
|
113,253 |
|
Operating lease right-of-use asset |
|
|
31,271 |
|
|
|
31,527 |
|
Finance lease right-of-use asset |
|
|
38,197 |
|
|
|
39,404 |
|
Intangible assets, net |
|
|
127,151 |
|
|
|
141,916 |
|
Goodwill |
|
|
66,710 |
|
|
|
66,710 |
|
Deposits and other assets |
|
|
26,185 |
|
|
|
21,859 |
|
Total assets |
|
$ |
920,521 |
|
|
$ |
893,487 |
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
19,139 |
|
|
$ |
24,624 |
|
Accrued liabilities |
|
|
83,190 |
|
|
|
76,651 |
|
Total current liabilities |
|
|
102,329 |
|
|
|
101,275 |
|
Operating lease liability |
|
|
35,491 |
|
|
|
35,767 |
|
Finance lease liability |
|
|
67,345 |
|
|
|
68,109 |
|
Deferred tax liability, net |
|
|
441 |
|
|
|
441 |
|
Other liabilities |
|
|
32,429 |
|
|
|
31,740 |
|
Total liabilities |
|
|
238,035 |
|
|
|
237,332 |
|
Stockholders' equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares |
|
|
- |
|
|
|
- |
|
Common stock, $0.001 par value; 150,000 shares authorized; 58,387 |
|
|
59 |
|
|
|
58 |
|
Additional paid-in capital |
|
|
1,651,465 |
|
|
|
1,586,056 |
|
Accumulated other comprehensive income |
|
|
2,384 |
|
|
|
3,303 |
|
Accumulated deficit |
|
|
(971,290 |
) |
|
|
(933,130 |
) |
Less treasury stock (28 shares as of March 31, 2026 and December 31, |
|
|
(132 |
) |
|
|
(132 |
) |
Total stockholders' equity |
|
|
682,486 |
|
|
|
656,155 |
|
Total liabilities and stockholders' equity |
|
$ |
920,521 |
|
|
$ |
893,487 |
|
18
|
JULY 29, 2026 |
Primary GAAP to Non-GAAP Reconciliations
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
|
|
Q2 2026 |
|
|
Q2 2025 |
|
||||||||||||||||||
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
||||||
Cost of sales |
|
$ |
34,016 |
|
|
|
(5,227 |
) |
(a)(b) |
|
28,742 |
|
|
$ |
26,896 |
|
|
|
(5,764 |
) |
(a)(b) |
$ |
21,132 |
|
Gross Margin |
|
|
81.7 |
% |
|
|
2.8 |
% |
|
|
84.5 |
% |
|
|
78.3 |
% |
|
|
4.7 |
% |
|
|
83.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Selling, general and administrative |
|
$ |
116,060 |
|
|
$ |
(4,404 |
) |
(c)(d)(e) |
$ |
111,656 |
|
|
$ |
83,375 |
|
|
$ |
(295 |
) |
(f) |
$ |
83,080 |
|
Loss from operations |
|
$ |
(17,267 |
) |
|
$ |
9,678 |
|
|
$ |
(7,589 |
) |
|
$ |
(22,689 |
) |
|
$ |
6,059 |
|
|
$ |
(16,630 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest expense |
|
$ |
(1,459 |
) |
|
$ |
369 |
|
(g) |
$ |
(1,090 |
) |
|
$ |
(1,151 |
) |
|
$ |
- |
|
|
$ |
(1,151 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net loss |
|
$ |
(18,377 |
) |
|
$ |
10,047 |
|
(h) |
$ |
(8,330 |
) |
|
$ |
(19,657 |
) |
|
$ |
6,059 |
|
(h) |
$ |
(13,598 |
) |
Basic and diluted net loss per |
|
$ |
(0.31 |
) |
|
$ |
0.17 |
|
|
$ |
(0.14 |
) |
|
$ |
(0.34 |
) |
|
$ |
0.10 |
|
|
$ |
0.24 |
|
19
|
JULY 29, 2026 |
Primary GAAP to Non-GAAP Reconciliations
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited
|
|
Year-to-Date Q2 2026 |
|
|
Year-to-Date Q2 2025 |
|
||||||||||||||||||
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
|
GAAP |
|
|
Adjustments |
|
|
Non-GAAP |
|
||||||
Cost of sales |
|
$ |
67,355 |
|
|
$ |
(13,949 |
) |
(a)(b) |
$ |
53,406 |
|
|
$ |
51,212 |
|
|
$ |
(11,287 |
) |
(a)(b) |
$ |
39,925 |
|
Gross Margin |
|
|
80.0 |
% |
|
|
4.1 |
% |
|
|
84.1 |
% |
|
|
77.8 |
% |
|
|
4.9 |
% |
|
|
82.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Selling, general and administrative |
|
$ |
209,003 |
|
|
$ |
(5,097 |
) |
(c)(d)(e) |
$ |
203,906 |
|
|
$ |
154,048 |
|
|
$ |
(295 |
) |
(f) |
$ |
153,753 |
|
Loss from operations |
|
$ |
(37,123 |
) |
|
$ |
19,046 |
|
|
$ |
(18,077 |
) |
|
$ |
(43,367 |
) |
|
$ |
11,582 |
|
|
$ |
(31,785 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Interest expense |
|
$ |
(10,128 |
) |
|
$ |
3,324 |
|
(c) |
$ |
(6,804 |
) |
|
$ |
(10,128 |
) |
|
$ |
3,324 |
|
(c) |
$ |
(6,804 |
) |
Interest expense |
|
$ |
(2,584 |
) |
|
$ |
369 |
|
(g) |
$ |
(2,215 |
) |
|
$ |
(2,314 |
) |
|
$ |
- |
|
|
$ |
(2,314 |
) |
Net loss |
|
$ |
(38,160 |
) |
|
$ |
19,415 |
|
(h) |
$ |
(18,745 |
) |
|
$ |
(37,803 |
) |
|
$ |
11,582 |
|
(h) |
$ |
(26,221 |
) |
Basic and diluted net loss per |
|
$ |
(0.65 |
) |
|
$ |
(0.33 |
) |
|
$ |
(0.32 |
) |
|
$ |
(0.66 |
) |
|
$ |
0.20 |
|
|
$ |
(0.46 |
) |
20
|
JULY 29, 2026 |
Additional GAAP to Non-GAAP Reconciliations
Reported Sales vs. Prior Periods (in thousands) |
|
|||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
Year-over-Year Percent Change |
|
|
Quarter-over-Quarter Percent Change |
|
|||||||||||||||||||||
|
|
1Q 2026 |
|
|
1Q 2025 |
|
|
4Q 2025 |
|
|
Reported |
|
|
Operations (1) |
|
|
Currency (2) |
|
|
Reported |
|
|
Operations (1) |
|
|
Currency (2) |
|
|||||||||
International |
|
$ |
36,631 |
|
|
$ |
31,251 |
|
|
$ |
35,808 |
|
|
|
17.2 |
% |
|
|
16.4 |
% |
|
|
0.8 |
% |
|
|
2.3 |
% |
|
|
2.6 |
% |
|
|
(0.3 |
%) |
Total Net Sales |
|
$ |
185,610 |
|
|
$ |
124,120 |
|
|
$ |
150,571 |
|
|
|
49.5 |
% |
|
|
49.3 |
% |
|
|
0.2 |
% |
|
|
23.3 |
% |
|
|
23.3 |
% |
|
|
0.0 |
% |
For Non-GAAP disclosures associated with the company’s past quarterly results, included with respect to the sequential comparisons included herein, please see reconciliations here.
21